For decades, cancer has carried a hidden accomplice — not the tumor itself, but a brain-mediated wasting process that quietly dismantles the body from within, leaving patients too weak to survive the very treatments meant to save them. Researchers at KAIST in South Korea have now traced this betrayal to its origin: a molecular signal hijacking the brainstem, commanding the body to consume itself. By silencing the receptor that receives this command, their RNA-based therapy achieved 90 percent survival in treated mice against 20 percent in untreated ones — a result that reframes cancer cachexia
KAIST Breakthrough: RNA Therapy Reverses Cancer Cachexia, Boosts Survival to 90%
Cancer cachexia affects 50-80% of cancer patients, causing severe physical decline, treatment discontinuation, and reduced survival rates due to progressive muscle and weight loss.
The cancer hijacks the brain's control center and tells it to dismantle the patient from the inside.
Mark
Why does the brain do this? Why would it respond to cancer by destroying the body?
Mimi
It's not malice—it's a signal gone wrong. GDF15 is normally a stress hormone. When the body is truly starving or severely ill, it tells the brain to conserve energy by breaking down reserves. Cancer hijacks that ancient survival mechanism. The tumor floods the system with GDF15, and the brain can't tell the difference between real starvation and cancer's deception.
Mark
So the therapy is essentially unplugging the receiver.
Mimi
Exactly. If the brainstem never produces the GFRAL receptor, the signal has nowhere to land. The cancer still secretes GDF15, but it's like shouting into an empty room. The body no longer gets the instruction to waste away.
Mark
Why did it take so long to figure this out?
Mimi
Most research focused on the body—on muscles, on metabolism, on appetite. The idea that the root cause lived in the brain, in a specific receptor in a specific part of the brainstem, required a different kind of thinking. It required looking at cancer cachexia not as a metabolic disease but as a neurological one.
Mark
The survival numbers seem almost too good. Ninety percent versus twenty percent.
Mimi
In mice, yes. That's why the next phase matters. Mice and humans are different. The therapy has to work in human tissue, in human complexity. But the principle is sound, and the preclinical evidence is strong enough that they're moving toward human trials.
Mark
What happens to a patient on this therapy while they're also getting chemotherapy?
Mimi
That's the real question. If the therapy preserves muscle and metabolic function, patients might tolerate chemo better, complete more cycles, respond more effectively. They might not have to stop treatment because their body has wasted away. That's where the survival benefit could come from in real patients.
Der Puls
- Cancer cachexia strikes up to 80% of cancer patients, dissolving muscle and fat even when patients eat adequately — a metabolic collapse driven not by hunger but by the brain's own misdirected commands.
- The wasting cycle is self-defeating: as the body weakens, chemotherapy becomes less tolerable and less effective, forcing doctors to reduce or abandon treatment precisely when it is most needed.
- KAIST researchers pinpointed the brainstem receptor GFRAL as the critical relay point where cancer's wasting signal lands, and used antisense oligonucleotides to silence it before it could be produced at all.
- In mice with advanced cachexia, the therapy dramatically slowed muscle and fat loss, restored metabolic function, and lifted survival rates from 20 percent to 90 percent — a margin that signals a genuine mechanistic breakthrough rather than incremental improvement.
- The treatment is envisioned as an adjuvant companion to chemotherapy, preserving patient strength and treatment tolerance rather than replacing existing cancer therapies.
- Preclinical work continues now, with human clinical trials targeted for 2030 — a measured but meaningful horizon for patients and families watching cachexia claim what the cancer itself has not yet taken.
For decades, cancer has carried a hidden accomplice — not the tumor itself, but a brain-mediated wasting process that quietly dismantles the body from within, leaving patients too weak to survive the very treatments meant to save them. Researchers at KAIST in South Korea have now traced this betrayal to its origin: a molecular signal hijacking the brainstem, commanding the body to consume itself. By silencing the receptor that receives this command, their RNA-based therapy achieved 90 percent survival in treated mice against 20 percent in untreated ones — a result that reframes cancer cachexia not as an inevitable shadow of disease, but as a targetable mechanism. Clinical trials are projected for 2030, placing a potential answer within reach of the millions for whom this complication has meant the difference between life and death.
Cancer cachexia works in a way most people do not expect. The patient eats. Sometimes they eat well. But the body refuses to hold what it receives — muscle dissolves, fat disappears, and within months a person has wasted away not from starvation but from a metabolic process their own brain is driving. This complication touches between half and four-fifths of all cancer patients, and it is one of the primary reasons chemotherapy fails: as the body weakens, treatment becomes intolerable, doctors pull back, and survival rates fall. Until now, medicine has offered little beyond appetite stimulants — drugs that address the surface, not the source.
Researchers at KAIST, working through their faculty startup THOR Therapeutics, traced the problem to its true origin. When cancer spreads, it floods the body with a protein called GDF15, which travels to the brainstem and binds to a receptor called GFRAL. That binding sends a command: stop eating, start consuming the body's own muscle and fat. The cancer, in effect, hijacks the brain's control center. The KAIST team, led by Professors Minho Shong and Jinkuk Kim, decided to remove the receiver entirely. Using antisense oligonucleotides — an RNA-based approach that silences genes before they produce proteins — they prevented the brainstem from manufacturing GFRAL at all, leaving the wasting signal with nowhere to land.
The results in mice with already-advanced cachexia were striking. Muscle and fat loss slowed sharply. Metabolic function began to recover. By around day 50, treated animals showed a 90 percent survival rate; untreated animals, 20 percent. The gap was not incremental — it was transformative. Crucially, the therapy does not simply stimulate appetite. It dismantles the mechanism producing the wasting, which means it could work alongside chemotherapy as a companion treatment — preserving strength and metabolic health while cancer itself is being targeted.
Preclinical work continues, with human clinical trials projected for 2030. For patients and families watching cachexia claim a body while the mind remains present and aware, that timeline represents something genuinely new: not a management strategy, but a real possibility that this particular cruelty might one day be interrupted at its source.
Cancer cachexia is a quiet killer. It arrives as the disease itself progresses, and it works differently than most people imagine. The patient eats. They eat enough, sometimes more than enough. But their body refuses to hold onto what they consume. Muscle dissolves. Fat vanishes. Within months, the person has wasted away—not from starvation, but from a metabolic betrayal orchestrated by their own brain.
This complication strikes between half and four-fifths of all cancer patients, making it one of the disease's most common and most destructive companions. It is also one of the reasons chemotherapy fails. As the body weakens, treatment becomes less tolerable, less effective. Doctors stop. Patients decline faster. Survival rates plummet. Yet until now, medicine has had almost nothing to offer beyond appetite stimulants—drugs that address the symptom, not the cause.
Researchers at KAIST, South Korea's premier science and engineering university, have identified where the problem actually begins: not in the body's muscles or metabolism, but in the brain itself. When cancer cells spread, they release a protein called GDF15 in massive quantities. This protein travels to the brainstem, where it docks onto a receptor called GFRAL. Once that connection is made, the brain receives a signal—a command, really—to stop eating and start consuming the body's own stores of muscle and fat. The cancer, in effect, hijacks the brain's control center and tells it to dismantle the patient from the inside.
A team led by Professor Minho Shong and Professor Jinkuk Kim, working with their faculty startup THOR Therapeutics, decided to cut the signal at its source. They developed a therapy using antisense oligonucleotides—a form of RNA-based gene therapy that silences specific genes before they can be translated into proteins. Their target was GFRAL itself. By preventing the brainstem from ever producing this receptor, they reasoned, the cancer's wasting signal would have nowhere to land. The receiver would be gone.
They tested the approach in mice that already had advanced cachexia. The disease had progressed. The animals were already wasting. Then the researchers administered the treatment. What happened next was striking: muscle and fat loss slowed dramatically. Metabolic function, which had been shattered, began to restore itself. By around day 50 of the study, the treated mice showed a survival rate of 90 percent. The untreated group: 20 percent. The difference was not marginal. It was transformative.
What makes this work distinct from existing therapies is that it does not merely coax the appetite back. It dismantles the mechanism driving the wasting in the first place. The researchers believe the treatment could eventually work alongside standard chemotherapy, not as a replacement but as a companion—something that preserves the patient's strength and metabolic health while poison is being delivered to the cancer. Better quality of life. Better tolerance for treatment. Better survival.
The path forward is measured. Preclinical work continues now. Clinical trials in human patients are targeted for 2030. Commercialization will follow after that. But for patients and families watching cancer cachexia steal a loved one's body while they remain conscious and aware, the timeline represents something that did not exist before: a real possibility that this particular cruelty might one day be stopped.
Bemerkenswerte Zitate
Unlike existing treatments that only stimulate appetite, this therapy directly targets the key receptor in the brainstem at the RNA level to suppress the root cause of cancer cachexia— Professor Minho Shong, KAIST
Möchten Sie die ganze Geschichte?
Das Original lesen bei EurekAlert! ↗
Health & Medicine